Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"JANSSEN NZ LIMITED, Consumer",Guselkumab,"Plaque psoriasis, moderate to severe, 1st line biologic",Guselkumab (TREMFYA),Options for investment,Community and Hospital,Dermatologicals
